On 5 August 2013, orphan designation (EU/3/13/1176) was granted by the European Commission to Bone Therapeutics SA, Belgium, for human allogeneic bone-marrow-derived osteoblastic-like cells for the treatment of non-traumatic osteonecrosis.
Human allogeneic bone-marrow-derived osteoblastic-like cells
Treatment of non-traumatic osteonecrosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|December 2022||The sponsor’s name was changed from Bone Therapeutics SA to BioSenic and the address was updated.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: